Compare Alexandria Real Estate Equities Inc (ARE) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alexandria Real Estate Equities Inc vs IDEXX Laboratories, Inc. — how do they compare? Alexandria Real Estate Equities Inc trades at $48.06 (market cap $8.28B), while IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 5.6× Alexandria Real Estate Equities Inc's market cap, and Alexandria Real Estate Equities Inc pays a 5.99% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| ARE | IDXX | |
|---|---|---|
Market Cap | $8.28B | $46.22B |
Sector | Real Estate | Health |
52-Week High | $87.45 | $766.68 |
52-Week Low | $40.41 | $526.44 |
Enterprise Value | $20.98B | $47.12B |
Dividend Yield | 5.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alexandria Real Estate Equities (ARE) trades at $48.07, down 0.58% on the day, with a bearish technical signal and mixed earnings. The stock shows negative profitability metrics, including a net income margin of -37.12% and ROE of -6.29%, though it beat FFO estimates in Q2 2026. Recent news highlights leasing momentum and a narrowed full-year FFO guidance range, while a pending lawsuit adds uncertainty.
The outlook remains cautious due to weak earnings and high debt, but the stock trades below book value, offering potential value. Risks include ongoing losses, litigation, and real estate market volatility. Analyst consensus is mixed with a $53.71 price target, suggesting modest upside if operational improvements materialize.
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alexandria Real Estate Equities Inc
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.
Read more on ARE →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
